Ergomed
Ergomed plc, a leading provider of specialised services to the pharmaceutical industry, is headquartered in Great Britain. Founded in 1997, the company has established a strong presence in key operational regions, including Europe and North America. Ergomed focuses on two main business areas: drug development and post-marketing services, offering a unique blend of expertise that enhances the efficiency of clinical trials. With a commitment to quality and innovation, Ergomed provides a range of core services, including clinical research, pharmacovigilance, and regulatory affairs. The company has achieved notable milestones, such as its successful listing on the London Stock Exchange, solidifying its position as a trusted partner in the life sciences sector. Ergomed's dedication to tailored solutions and client satisfaction sets it apart in a competitive market.
DitchCarbon Score
How does Ergomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ergomed's score of 29 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ergomed's reported carbon emissions
In 2022, Ergomed reported total carbon emissions of approximately 46,150 kg CO2e. This figure includes 730 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and 14,290 kg CO2e from Scope 2 emissions related to purchased electricity. Notably, the majority of their emissions, about 17,290 kg CO2e, stemmed from Scope 3, specifically business travel. Comparatively, in 2021, Ergomed's total emissions were about 60,650 kg CO2e, with Scope 1 emissions at 60 kg CO2e, Scope 2 emissions at 25,450 kg CO2e, and Scope 3 emissions at 17,530 kg CO2e. This indicates a significant reduction in total emissions of approximately 14,500 kg CO2e from 2021 to 2022. Despite these reductions, Ergomed has not publicly committed to specific reduction targets or initiatives, such as those aligned with the Science Based Targets initiative (SBTi). Their climate commitments remain vague, with no documented reduction targets or climate pledges available. As a company headquartered in Great Britain, Ergomed is positioned within an industry increasingly focused on sustainability and carbon footprint reduction, yet further clarity on their long-term climate strategy would be beneficial.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 60 | 000 |
| Scope 2 | 25,450 | 00,000 |
| Scope 3 | 17,530 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ergomed is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
